Login to Your Account


Wednesday, May 16, 2018

Meiragtx Holdings plc, of New York, has filed to raise up to $86 million in an IPO. Once the offering has priced the company expects that its shares will trade on the Nasdaq under the symbol MGTX. Using gene therapies, it will develop a product pipeline focused on inherited retinal diseases, severe forms of xerostomia and neurodegenerative diseases.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription